The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study

Radiotherapy and Oncology

Volumn 80, Issue 2, 2006, Pages 123-131

  Nordsmark, Marianne ^a,b,f   Loncaster, Julie ^c   Aquino Parsons, Christina ^d   Chou, Shu Chuan ^e   Gebski, Val ^f,g   West, Catharine ^c   Lindegaard, Jacob C ^b   Havsteen, Hanne ^b   Davidson, Susan E ^c   Hunter, Robin ^c   Raleigh, James A ^e   Overgaard, Jens ^a  

^a Department of Experimental Clinical Oncology ^*  (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f WESTMEAD HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hypoxia marker; Pimonidazole; Tumour oxygenation; Uterine cervix carcinoma

Indexed keywords

BIOLOGICAL MARKER; CARBOGEN; CISPLATIN; HEMOGLOBIN; PIMONIDAZOLE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMICAL LABELING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; HYPOXEMIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; OXYGEN TENSION; PRIORITY JOURNAL; PROGNOSIS; STAINING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR BIOPSY; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; FEMALE; HUMANS; MIDDLE AGED; NITROIMIDAZOLES; OXYGEN; PARTIAL PRESSURE; PROGNOSIS; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; UTERINE CERVICAL NEOPLASMS;

EID: 33748165246     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.07.010     Document Type: Article

References (48)

1. Vaupel P., Kelleher D.K., and Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28 (2001) 29-35
2. Gray H.L., Conger A.D., Ebert M., Hornsey S., and Scott O.C.A. The concentration of oxygen dissolved in the tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
3. Horsman M.R., Khalil A.A., Nordsmark M., Grau C., and Overgaard J. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiother Oncol 28 (1993) 69-71
4. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev Cancer 2 (2002) 38-47
5. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26 (1993) 45-50
6. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
7. Höckel M., Schlenger K., Aral B., Mitze M., Schäffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
8. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20 (2002) 680-687
9. Dische S., Machin D., and Chassagne D. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 26 (1993) 93-103
10. Kennedy A.S., Raleigh J.A., Perez G.M., et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37 (1997) 897-905
11. Varia M.A., Calkins-Adams D.P., Rinker L.H., et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71 (1998) 270-277
12. Raleigh J.A., Chou S.C., Bono E.L., Thrall D.E., and Varia M.A. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 49 (2001) 569-574
13. Cline J.M., Rosner G.L., Raleigh J.A., and Thrall D.E. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int J Radiat Oncol Biol Phys 37 (1997) 655-662
14. Thrall D.E., Rosner G.L., Azuma C., McEntee M.C., and Raleigh J.A. Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol 44 (1997) 171-176
15. Kleiter M.M., Thrall D.E., Malarkey D.E., et al. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys 64 (2006) 592-602
16. Raleigh J.A., Chou S.C., Arteel G.E., and Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
17. Arcasoy M.O., Amin K., Karayal A.F., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82 (2002) 911-918
18. Hoskin P.J., Sibtain A., Daley F.M., Saunders M.I., and Wilson G.D. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 72 (2004) 159-168
19. Hoskin P.J., Sibtain A., Daley F.M., and Wilson G.D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89 (2003) 1290-1297
20. Bussink J., Kaanders J.H., and van der Kogel A.J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67 (2003) 3-15
21. Haustermans K., Hofland I., Van de P.L., et al. Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiother Oncol 55 (2000) 325-333
22. Begg A.C., Janssen H., Sprong D., et al. Hypoxia and perfusion measurements in human tumors - initial experience with pimonidazole and IUdR. Acta Oncol 40 (2001) 924-928
23. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
24. Nordsmark M., Loncaster J., quino-Parsons C., et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 67 (2003) 35-44
25. Bentzen S.M. Radiobiological considerations in the design of clinical trials. Radiother Oncol 32 (1994) 1-11
26. Hunter RD. The female genital tract. In: Pointon R.C.S. (Ed). The radiotherapy of malignant disease (1991), Springer-Verlag, London 279-308
27. Aquino-Parsons C., Green A., and Minchinton A.I. Oxygen tension in primary gynaecological tumours: the influence of carbon dioxide concentration. Radiother Oncol 57 (2000) 45-51
28. 2 tension measurements. Cancer Res 51 (1991) 6098-6102
29. Nordsmark M., Bentzen S.M., and Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of i. Acta Oncol 33 (1994) 383-389
30. Wong R.K., Fyles A., Milosevic M., Pintilie M., and Hill R.P. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumor variability, probe position, and track depth. Int J Radiat Oncol Biol Phys 39 (1997) 405-412
31. Thews O., and Vaupel P. Relevant parameters for describing the oxygenation status of solid tumors. Strahlenther Onkol 172 (1996) 239-243
32. Korn E.L. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5 (1986) 255-260
33. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 1 (2005) 18-24
34. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
35. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53 (1999) 99-104
36. Lyng H., Sundfor K., and Rofstad E.K. Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int J Radiat Oncol Biol Phys 46 (2000) 935-946
37. Haensgen G., Krause U., Becker A., et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys 50 (2001) 865-872
38. Loncaster J.A., Carrington B.M., Sykes J.R., et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54 (2002) 759-767
39. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastas 20 (2003) 237-250
40. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
41. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 α and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
42. Olive P.L., Aquino-Parsons C., MacPhail S.H., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61 (2001) 8924-8929
43. Jankovic B., quino-Parsons C., Raleigh J.A., et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom 70 (2006) 45-55
44. Hicks R.J., Rischin D., Fisher R., Binns D., Scott A.M., and Peters L.J. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32 (2005) 1384-1391
45. Azuma Y., Chou S.C., Lininger R.A., Murphy B.J., Varia M.A., and Raleigh J.A. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. Clin Cancer Res 9 (2003) 4944-4952
46. Chou S.C., Azuma Y., Varia M.A., and Raleigh J.A. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 90 (2004) 728-735
47. Rischin D., Peters L., Fisher R., et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
48. Kaanders J.H., Bussink J., and van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 (2002) 728-737